Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

cfDNA Assay Multicenter Prospective Observational Validation for Early Cancer Detection, Minimal Residual Disease, and Relapse

NCT05366881 is registered in ClinicalTrials.gov with Adela, Inc as lead sponsor.

NCT NCT05366881
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05366881 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
cfDNA Assay Multicenter Prospective Observational Validation for Early Cancer Detection, Minimal Residual Disease, and Relapse
Lead sponsor
Adela, Inc
Phase
Observational
Overall status
Recruiting
Start date
May 3, 2022
Completion date
March 31, 2027
Enrollment
7,000 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, brain cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, esophageal cancer, head and neck cancer, hepatobiliary cancer, leukemia, lung cancer, lymphoma, multiple myeloma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, sarcoma, stomach cancer, thyroid cancer